Similar articles

Abstract: Objective: To study the effect of glycine site/NMDA (N-methyl-D-aspartate) receptor antagonist MRZ2/576 on the conditioned place preference (CPP) and locomotor activity induced by morphine in mice. Methods: Different doses (1.25, 2.5 and 5 mg/kg, i.p.) of MRZ2/576 were used to evaluate the effect of MRZ2/576 on the acquisition and expression of CPP induced by morphine (5 mg/kg) in mice. In addition, we examined the locomotor activity of mice in conditioning and testing phase of CPP paradigm. Results: MRZ2/576 alone could not establish place preference, but a 5 mg/kg dose of MRZ2/576 could block both acquisition and expression of morphine-induced CPP. In testing phase of CPP, there was no statistical difference for locomotor activity between the groups; injection of MRZ2/576 showed a dose-dependent decrease of locomotor activity on both control and morphine-treated mice, especially 5 mg/kg of MRZ2/576 significantly suppressed the locomotor activity of mice. Conclusion: Based on the present results, we assume that MRZ2/576 can antagonize the rewarding effect of morphine, suggesting that this glycine site/NMDA receptor antagonist could be used to treat addictions due to its light side effect profile.

[1] Bäckström, P., Hyytia, P., 2006. Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology, 31(4):778-786.

[2] Bajo, M., Crawford, E.F., Roberto, M., Madamba, S.G., Siggins, G.R., 2006. Chronic morphine treatment alters expression of N-methyl-D-aspartate receptor subunits in the extended amygdala. J. Neurosci. Res., 83(4):532-537.

[3] Belozertseva, I.V., Danysz, W., Bespalov, A.Y., 2000a. Short-acting NMDA receptor antagonist MRZ2/576 produces prolonged suppression of morphine withdrawal in mice. Naunyn-Schmiedeberg’s Arch. Pharmacol., 361(3):279-282.

[4] Belozertseva, I.V., Danysz, W., Bespalov, A.Y., 2000b. Effects of short-acting NMDA receptor antagonist MRZ2/576 on morphine tolerance development in mice. Naunyn-Schmiedeberg’s Arch. Pharmacol., 361(6):573-577.

[5] Bienkowski, P., Korso, E., Kostowski, W., Danysz, W., 1999. Effects of N-methyl-D-aspartate receptor antagonists on reinforced and nonreinforced responding for ethanol in rats. Alcohol, 18(2-3):131-137.

[6] Carlezon, W.A.Jr, Kosten, T.A., Nestler, E.J., 2000. Behavioral interactions caused by combined administration of morphine and MK-801 in rats. Psychopharmacology, 151(2-3):261-272.

[7] Danysz, W., Parsons, C.G., Karcz-Kubicha, M., Schwaier, A., Popik, P., Wedzony, K., Lazarewicz, J., Quack, G., 1998. GlycineB antagonist as potential therapeutic agents. Previous hopes and present reality. Amino Acids, 14(1-3):235-239.

[8] Danysz, W., Kozelab, E., Parsons, C.G., Sladek, M., Bauer, T., Popik, P., 2005. Peripherally acting NMDA receptor/glycineB site receptor antagonists inhibit morphine tolerance. Neuropharmacology, 48(3):360-371.

[9] del Rosario, C.N., Pacchioni, A.M., Cancela, L.M., 2002. Influence of acute or repeated restraint stress on morphine-induced locomotion: involvement of dopamine, opioid and glutamate receptors. Behav. Brain Res., 134(1-2):229-238.

[10] Franken, I.H., Booij, J., van den Brink, W., 2005. The role of dopamine in human addiction: from reward to motivated attention. Eur. J. Pharmacol., 526(1-3):199-206.

[11] Harris, G.C., Wimmer, M., Byrne, R., Aston-Jones, G., 2004. Glutamate-associated plasticity in the ventral tegmental area is necessary for conditioning environmental stimuli with morphine. Neuroscience, 129(3):841-847.

[12] Kiefer, F., Jahn, H., Koester, A., Montkowski, A., Reinscheid, R.K., Wiedemann, K., 2003. Involvement of NMDA receptors in alcohol-mediated behavior: mice with reduced affinity of the NMDA R1 glycine binding site display an attenuated sensitivity to ethanol. Biol. Psychiatry, 53(4):345-351.

[13] Kretschmer, B.D., 1998. Ligand of the NMDA receptor-associated glycine recognition site and motor behavior. Amino Acids, 14(1-3):227-234.

[14] Liu, Y., Hill, R.H., Arhem, P., von Euler, G., 2001. NMDA and glycine regulate the affinity of the Mg²⁺-block site in NR1-1a/NR2A NMDA receptor channels expressed in Xenopus oocytes. Life Sci., 68(16):1817-1826.

[15] Makarska-Bialek, K., Kaminski, R.M., Czuczwar, S.J., 2005. Influence of the antagonist of the glycine site of NMDA receptors, MRZ2/576, on the anticonvulsant activity of conventional antiepileptic drugs in mice. Pharmacol. Rep., 57(4):458-466.

[16] Narita, M., Aoki, T., Suzuki, T., 2000. Molecular evidence for the involvement of NR2B subunit containing N-methyl-D-aspartate receptors in the development of morphine-induced place preference. Neuroscience, 101(3):601-606.

[17] Narita, M., Aoki, T., Ozaki, S., Yajima, Y., Suzuki, T., 2001. Involvement of protein kinase Cγ isoform in morphine induced reinforcing effects. Neuroscience, 103(2):309-314.

[18] Narita, M., Kato, H., Miyoshi, K., Aoki, T., Yajima, Y., Suzuki, T., 2005. Treatment for psychological dependence on morphine: usefulness of inhibiting NMDA receptor and its associated protein kinase in the nucleus accumbens. Life Sci., 77(18):2207-2220.

[19] Nestler, E.J., 2005. Is there a common molecular pathway for addiction? Nat. Neurosci., 8(11):1445-1449.

[20] Panos, J.J., Rademacher, D.J., Renner, S.L., Steinpreis, R.E., 1999. The rewarding properties of NMDA and MK-801 (Dizocilpine) as indexed by the conditioned place preference paradigm. Pharmacol. Biochem. Behav., 64(3):591-595.

[21] Papp, M., Gruca, P., Willner, P., 2002. Selective blockade of drug-induced place preference conditioning by ACPC, a functional NDMA-receptor antagonist. Neuropsychopharmacology, 27(5):727-744.

[22] Parsons, C.G., Danysz, W., Bartmann, A., Spielmanns, P., Frankiewicz, T., Hesselink, M., Eilbacher, B., Quack, G., 1999. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology, 38(1):85-108.

[23] Pláteník, J., Kuramoto, N., Yoneda, Y., 2000. Molecular mechanisms associated with long-term consolidation of the NMDA signal. Life Sci., 67(4):335-364.

[24] Quartaroli, M., Fasdelli, N., Bettelini, L., Maraia, G., Corsi, M., 2001. GV196771A, an NMDA receptor/glycine site antagonist, attenuates mechanical allodynia in neuropathic rats and reduces tolerance induced by morphine in mice. Eur. J. Pharmacol., 430(2-3):219-227.

[25] Rezayof, A., Zarrindast, M.R., Sahraei, H., Haeri-Rohani, A., 2003. Involvement of dopamine receptors of the dorsal hippocampus on the acquisition and expression of morphine-induced place preference in rats. J. Psychopharmacol., 17(4):415-423.

[26] Schildein, S., Agmo, A., Huston, J.P., Schwarting, R.K., 1998. Intraacumbens injections of substance p, morphine, and amphetamine: effect on conditioned place preference and behavioral activity. Brain Res., 790(1-2):185-194.

[27] Tzschentke, T.M., 1998. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issue. Prog. Neurobiol., 56(6):613-672.

[28] Tzschentke, T.M., 2001. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog. Neurobiol., 63(3):241-320.

[29] Tzschentke, T.M., 2002. Glutamatergic mechanisms in different disease state: overview and therpeutical implication—an introduction. Amino Acids, 23(1-3):147-152.

[30] Xi, Z.X., Stein, E.A., 2002. Blockade of ionotropic glutamatergic transmission in the ventral tegmental area reduces heroin reinforcement in rat. Psychopharmacology, 164(2):144-150.

[31] Zarrindast, M.R., Azami, B.N., Rostami, P., Rezayof, A., 2006. Repeated administration of dopaminergic agents in the nucleus accumbens and morphine-induced place preference. Behav. Brain Res., 169(2):248-255.

[32] Zhu, H., Ho, I.K., 1998. NMDA-R1 antisense oligonucleotide attenuate withdrawal signs from morphine. Eur. J. Pharmacol., 352(2-3):151-156.